Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
8
×
clinical trials
8
×
life sciences
national blog main
boston blog main
national top stories
biotech
boston top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
alnylam pharmaceuticals
fda
inclisiran
national
new york
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
roche
sanofi
bristol-myers squibb
cancer
cholesterol
deals
ifm therapeutics
indiana blog main
indiana top stories
investing
mark timney
merck
novartis
pcsk9
pcsk9 inhibitors
praluent
purdue pharma
repatha
san diego blog main
san diego top stories
What
drug
8
×
medicines
cholesterol
fda
medco
new
pricing
approval
bio
brings
cancer
decades
lowering
market
medicine
roundup
twice
aces
acquire
acute
addresses
advanced
advantages
agreed
amgen
amgen’s
announced
arrival
award
bar
big
billion
bringing
carries
cash
causes
ceo
clears
closer
company
Language
unset
8
×
Current search:
drug
×
amgen
×
" clinical trials "
×
unset
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing